Pre-made Loncastuximab benchmark antibody ( Whole mAb ADC, anti-CD19 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-320
Anti-CD19 therapeutic antibody (Pre-made Loncastuximab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Loncastuximab tesirine is an antibody-drug conjugate designed to target human CD19. It is a humanized monoclonal antibody and conjugated to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin by a protease enzyme cleavable valine-alanine linker.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD19 therapeutic antibody (Pre-made Loncastuximab biosimilar,Whole mAb ADC)|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||6ani:HL:IM|
|95-98% SI Structure||None|
|Conditions Approved||Diffuse large B cell lymphoma|
|Conditions Active||Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma|
|Conditions Discontinued||Precursor B-cell lymphoblastic leukaemia-lymphoma|